sellWeak
John Nuss sold $2,019 of VTYX
CHIEF SCIENTIFIC OFFICER at Ventyx Biosciences, Inc.. 1,887 shares at an average of $1.07, traded Apr 2, 2025, filed Apr 3, 2025.
Warning score
15Value
$2,019
1,887 shares
Holdings after
467,226
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- 0Share of holdings soldSold 0.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-009944, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 2, 2025 | SOpen-market sale Common Stock | -1,887 | $1.07 | $2,019 | 467,226 | Apr 3, 2025 |
Related signals
Other insiders at Ventyx Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $365k 47,345 shares | -2% | |
| 18Weak | Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $98k 12,675 shares | -3% | |
| 22Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $50k 21,119 shares | -4% | |
| 37Weak | VTYXbuy Ventyx Biosciences, Inc. | Sheila Gujrathi director | $301k 130,000 shares | - | |
| 5Weak | VTYXsell Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $30k 13,161 shares | -3% | |
| 55Moderate | VTYXbuy Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $960k 500,000 shares | +30% | |
| 37Weak | Ventyx Biosciences, Inc. | Martin Auster CHIEF FINANCIAL OFFICER | $7,592 1,405 shares | -5% | |
| 30Weak | Ventyx Biosciences, Inc. | Christopher W Krueger CHIEF BUSINESS OFFICER | $8,921 1,651 shares | -1% | |
| 40Moderate | Ventyx Biosciences, Inc. | Raju Mohan CEO AND PRESIDENT | $23k 4,312 shares | -0% | |
| 30Weak | Ventyx Biosciences, Inc. | John Nuss CHIEF SCIENTIFIC OFFICER | $8,921 1,651 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.